TR201901877A2 - FORMULATIONS AND PREPARATION METHODS THAT INCREASE LANTHAN CARBONATE'S BIOACTIVITY - Google Patents
FORMULATIONS AND PREPARATION METHODS THAT INCREASE LANTHAN CARBONATE'S BIOACTIVITY Download PDFInfo
- Publication number
- TR201901877A2 TR201901877A2 TR2019/01877A TR201901877A TR201901877A2 TR 201901877 A2 TR201901877 A2 TR 201901877A2 TR 2019/01877 A TR2019/01877 A TR 2019/01877A TR 201901877 A TR201901877 A TR 201901877A TR 201901877 A2 TR201901877 A2 TR 201901877A2
- Authority
- TR
- Turkey
- Prior art keywords
- carbonate
- bioactivity
- lanthan
- formulations
- increase
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 4
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 title 1
- FZLIPJUXYLNCLC-UHFFFAOYSA-N lanthanum atom Chemical compound [La] FZLIPJUXYLNCLC-UHFFFAOYSA-N 0.000 title 1
- 238000002360 preparation method Methods 0.000 title 1
- 229910017569 La2(CO3)3 Inorganic materials 0.000 abstract 3
- 238000009472 formulation Methods 0.000 abstract 3
- NZPIUJUFIFZSPW-UHFFFAOYSA-H lanthanum carbonate Chemical compound [La+3].[La+3].[O-]C([O-])=O.[O-]C([O-])=O.[O-]C([O-])=O NZPIUJUFIFZSPW-UHFFFAOYSA-H 0.000 abstract 3
- 229960001633 lanthanum carbonate Drugs 0.000 abstract 3
- 102000006335 Phosphate-Binding Proteins Human genes 0.000 abstract 1
- 108010058514 Phosphate-Binding Proteins Proteins 0.000 abstract 1
- 238000004090 dissolution Methods 0.000 abstract 1
- 239000002245 particle Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/244—Lanthanides; Compounds thereof
Abstract
Mevcut buluş biyoaktivitesi arttırılmış lantan karbonat formülasyonunu kapsar. Partikül büyüklüğü D50 değeri 2 ?m?den az lantan karbonat içeren formülasyonun çözünme hızı 37°C±0.5°C sıcaklıkta 900 ml pH 1.2 ortamında 2 saat sonra minimum %65 olup, fosfat bağlama kapasitesi öğütülmemiş lantan karbonat içeren formülasyona göre önemli ölçüde yüksektir.The present invention encompasses the lanthanum carbonate formulation with enhanced bioactivity. The dissolution rate of the formulation with particle size D50 value less than 2? M? Lanthanum carbonate is minimum 65% after 2 hours at 37 ° C ± 0.5 ° C in 900 ml pH 1.2 environment, and its phosphate binding capacity is significantly higher than the formulation containing non-milled lanthanum carbonate.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TR2019/01877A TR201901877A2 (en) | 2019-02-07 | 2019-02-07 | FORMULATIONS AND PREPARATION METHODS THAT INCREASE LANTHAN CARBONATE'S BIOACTIVITY |
| PCT/TR2020/050038 WO2020162851A1 (en) | 2019-02-07 | 2020-01-20 | Formulations increasing bioactivity of lantanum carbonate and methods of their preparation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TR2019/01877A TR201901877A2 (en) | 2019-02-07 | 2019-02-07 | FORMULATIONS AND PREPARATION METHODS THAT INCREASE LANTHAN CARBONATE'S BIOACTIVITY |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TR201901877A2 true TR201901877A2 (en) | 2019-04-22 |
Family
ID=67981173
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TR2019/01877A TR201901877A2 (en) | 2019-02-07 | 2019-02-07 | FORMULATIONS AND PREPARATION METHODS THAT INCREASE LANTHAN CARBONATE'S BIOACTIVITY |
Country Status (2)
| Country | Link |
|---|---|
| TR (1) | TR201901877A2 (en) |
| WO (1) | WO2020162851A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115813867A (en) * | 2022-12-01 | 2023-03-21 | 山东齐都药业有限公司 | Lanthanum carbonate freeze-dried tablet and preparation method thereof |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8263119B2 (en) * | 2010-12-01 | 2012-09-11 | Shire Llc | Capsule formulations containing lanthanum compounds |
| CN102432055B (en) * | 2011-09-23 | 2013-10-16 | 北京大学 | Lanthanum carbonate nano-particles for treating hyperphosphatemia, preparation method and use thereof |
-
2019
- 2019-02-07 TR TR2019/01877A patent/TR201901877A2/en unknown
-
2020
- 2020-01-20 WO PCT/TR2020/050038 patent/WO2020162851A1/en active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| WO2020162851A1 (en) | 2020-08-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2016009666A (en) | Topical delivery of skin compositions having low ph. | |
| PH12021550992A1 (en) | Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use as atr kinase inhibitors | |
| MX2016010213A (en) | Novel pharmaceutical formulations. | |
| MX2017012878A (en) | Multicomponent gummy compositions with hard core. | |
| TW200744677A (en) | Compositions and methods for preparation of poorly water soluble drugs with increased stability | |
| GB0814302D0 (en) | Compounds and methods | |
| MX2018014631A (en) | Liquid neurotoxin formulation stabilized with tryptophan or tyrosine. | |
| EA201791138A1 (en) | PHARMACEUTICAL COMPOSITION, ITS PREPARATION AND APPLICATIONS | |
| WO2018143552A3 (en) | Injectable composition for preventing hair loss or stimulating hair growth | |
| PH12020551500A1 (en) | Viscosity reduction of highly concentrated protein formulations | |
| MX2021015543A (en) | Pyrimidine derivative inhibiting growth of cancer cell and medicinal use thereof. | |
| ATE453382T1 (en) | POWDER FOR NASAL ADMINISTRATION OF ACTIVE INGREDIENTS | |
| TR201901877A2 (en) | FORMULATIONS AND PREPARATION METHODS THAT INCREASE LANTHAN CARBONATE'S BIOACTIVITY | |
| EA200801614A1 (en) | PHARMACEUTICAL COMPOSITION CONTAINING MONTELUKAST | |
| WO2017091767A3 (en) | Drug formulations for cancer treatment | |
| MX2010004556A (en) | Pharmaceutical formulation of clavulanic acid. | |
| MX2021015721A (en) | Oral care compositions and methods of use. | |
| MY189759A (en) | Conjugate of finasteride with peptide | |
| EA201892842A1 (en) | PHARMACEUTICAL COMPOSITIONS, INCLUDING SAFINAMID | |
| MX2022003754A (en) | Oral care compositions comprising hops beta acid and fluoride. | |
| EP4248947A3 (en) | Dispersible compositions | |
| MX2021008022A (en) | Heterodimeric proteins for modulating gamma delta t cells. | |
| WO2023023304A3 (en) | Methods and compositions for delivery to and across the blood brain barrier | |
| WO2016205397A3 (en) | Target-specific delivery of therapeutic agents | |
| WO2019132579A3 (en) | Immunotoxin comprising ribonuclease fused to cytotransmab |